Currently, research on therapeutic targets for MPNST has developed rapidly and it is likely that in the near future clinical trials will incorporate therapies that inhibit components of the epigenetic machinery; however, clinical trials of therapies vary greatly, probably because they focus on pathways related to NF1 and not on sporadic cases [20]. Here, NF1 is linked to malignant peripheral nerve sheath tumor.